News | Radiation Therapy | November 06, 2017

Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust

Other factors, including prognosis, influenced noncompliance; researchers say building trust in medical institutions key

Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust

November 6, 2017 — Nearly one-third of women with breast cancer went against their doctor’s advice and chose not to begin or complete recommended adjuvant therapy to kill residual tumor cells following surgery, according to a study led by a Johns Hopkins Bloomberg School of Public Health researcher.

A survey that included 2,754 breast cancer patients in Florida and Pennsylvania during a two-year period found that this “treatment discordance” — not following a doctor’s recommended treatment plan in its entirety — was more likely among patients who reported a general distrust of medical institutions and insurers. The patients’ trust or distrust of their own doctors did not seem to be a factor.

Small studies in the past have found that some patients refuse their doctors’ advice and choose not to undergo or complete adjuvant therapy after breast cancer surgery. The new study, published in Cancer Epidemiology, Biomarkers & Prevention, is by far the largest evaluation of this issue, and suggests that the avoidance of adjuvant therapy is significant and is linked to a general distrust in the healthcare system.

“If we want more women with breast cancer to complete their treatment, we’ll need to deal with their beliefs about the healthcare system — and I do think we can modify those beliefs,” said Lorraine T. Dean, ScD, assistant professor in the Bloomberg School’s Department of Epidemiology and the study’s lead author.

Adjuvant therapy for breast cancer normally consists of a course of chemotherapy, hormone therapy or radiation treatment, and is meant to kill any cancer cells not removed by the initial surgery. Research has shown that adjuvant therapy on average reduces the likelihood of breast cancer’s recurrence and increases patients’ chances of long-term survival.

Yet it has long been clear that many patients either do not start their prescribed adjuvant therapy or start it but do not complete it. Cancer epidemiologists would like to know the causes of this treatment discordance, or noncompliance, in the hopes of improving treatment compliance, and thus improving patients’ long-term outcomes.

Prior studies, which were smaller in sample size and geographic scope, have linked breast cancer adjuvant treatment discordance to patients’ lack of trust in the general healthcare system, but have not been clear about whether or not distrust in the system is separate from distrust in physicians. Dean and colleagues sought to clarify this issue of trust with a large survey of breast cancer patients in two major U.S. states. The researchers mailed survey questions to all women in Pennsylvania and Florida cancer registries who were diagnosed with invasive but still localized breast cancer between 2005 and 2007 and were under the age of 65 at the time of diagnosis.

The response rate was 61 percent and the final sample included 2,754 women. Sixty-nine percent of patients were white, 27 percent were Black/African-American and four percent identified as another race or ethnicity. About 69.8 percent of these women indicated that they had received all of the adjuvant treatments their doctor had recommended. The remainder, 30.2 percent, indicated that they had elected not to receive at least one prescribed adjuvant treatment. More than half of the latter, or 18 percent of the cohort, had not undergone some or all of the recommended hormone therapy; the rest were evenly split between discordance with radiation treatment and discordance with chemotherapy.

“While it is surprising in general that nearly one-third of patients are not following up with recommended adjuvant treatment, some earlier, more localized studies have reported even higher discordance rates, and it’s possible that our own figures would have been higher if we had followed patients for more than two years,” Dean notes.

The survey asked participants about their trust in their doctors and in the healthcare system in general. The researchers used the patients’ responses to place them into high and low categories of general healthcare system distrust, and found that those in the “high-distrust” category, compared to those in the lower-distrust category, were about 22 percent more likely to report not having followed their doctor’s full set of recommended treatments.

Treatment discordance was also significantly less common among married women, but more common among people with higher incomes, patients with stage 1 breast cancer, which has the best prognosis, and patients living in Florida at the time of diagnosis — the latter possibly due to Florida’s insurance laws, which cover a “second opinion” evaluation after a cancer diagnosis, Dean said.

The results confirm the link seen in prior, smaller studies between breast cancer treatment discordance and general distrust in the healthcare system. The findings also suggest that this general distrust of medical institutions and the associated treatment discordance are not significantly influenced by the patient’s attitude towards her own doctor — whom many patients trusted even when they did not trust the broader healthcare system.

“Improving healthcare system distrust may require strategies that are not solely focused on boosting physician trust,” Dean said.

A decision to avoid or stop adjuvant therapy would be a rational one in cases where treatment is unnecessary, she noted. However, in keeping with prior studies of adjuvant effectiveness, she and her colleagues found that patients reporting treatment discordance were 40 percent more likely to have a cancer recurrence during the study period — underscoring the importance of improving treatment compliance and, to that end, trust in the healthcare system.

“If ordinary businesses can learn to increase trust in their brands, why not the same with health care institutions?” Dean said.

For more information: www.cebp.aacrjournals.org

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...